Participants were randomly assigned to one of 9 treatment conditions, and received 16 weeks of active treatment. Eight conditions consisted of all possible combinations of naltrexone vs. placebo, acamprosate vs. placebo, and Combined Behavioral Therapy (CBI) vs. no CBI. All participants in these cells also received up to 9 sessions of Medication Management (MM) along with the study medication. The 9th cell received CBI only, without study medication or placebo or MM.